Table 1.
Summary of baseline characteristics (ITT population)
| GN-037 (N = 76) | CP (N = 77) | V (N = 37) | |
|---|---|---|---|
| Age (years) | |||
| Mean ± SD | 40 ± 12.4 | 40 ± 11.4 | 41 ± 12.5 |
| Median (min–max) | 40 (20–63) | 39 (20–64) | 41 (18–64) |
| Sex, n (%) | |||
| Female | 36 (47.4) | 31 (40.3) | 17 (45.9) |
| Male | 40 (52.6) | 46 (59.7) | 20 (54.1) |
| BMI | |||
| Mean ± SD | 28.0 ± 5.3 | 28.7 ± 5.6 | 29.3 ± 4.9 |
| Median (min–max) | 27.4 (18.0–45.8) | 28.0 (19.1–50.5) | 28.4 (20.8–39.1) |
| IGA, n (%) | |||
| 2-Mild | 36 (47.4) | 33 (42.9) | 18 (48.6) |
| 3-Moderate | 40 (52.6) | 44 (57.1) | 19 (51.4) |
| %BSA affected by psoriasis | |||
| Mean ± SD | 5.7 ± 3 | 6.4 ± 3.2 | 6.4 ± 3.2 |
| Median (min–max) | 5 (3–12) | 5 (3–12) | 6 (3–12) |
| Size of target lesion (cm2) | |||
| Mean ± SD | 29.0 ± 20.1 | 29.4 ± 18.8 | 28.0 ± 18.4 |
| Median (min–max) | 20 (16–100) | 20 (16–100) | 20 (16–96) |
ITT intent-to-treat, GN-037 investigational novel fixed topical combination, CP clobetasol 17-propionate, V vehicle, BMI body mass index, IGA Investigator’s Global Assessment Score, BSA body surface area